Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Year Ended December 31, 2024
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	46	$	—	$	46
Total Drug Products	46		—		46
Concentrate Products
Product Sales – Point-in-time	101,443		92,258		9,185
Total Concentrate Products	101,443		92,258		9,185
Net Revenue	$	101,489	$	92,258	$	9,231
In thousands	Year Ended December 31, 2023
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	2,338	$	—	$	2,338
Total Drug Products	2,338		—		2,338
Concentrate Products
Product Sales – Point-in-time	79,802		72,871		6,931
License Fee – Over time	1,472		1,472		—
Total Concentrate Products	81,274		74,343		6,931
Net Revenue	$	83,612	$	74,343	$	9,269

Schedule of Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	December 31, 2024		December 31, 2023		January 1, 2023
Accounts Receivable, net	$	8,291	$	10,901	$	6,259
Contract Liabilities, which are included in deferred license revenue	$	475	$	521	$	4,331

Schedule of Potentially Dilutive Securities

The following table includes the potential shares of common stock that were excluded from the computation of diluted EPS per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	As of December 31,
	2024	2023
Warrants to Purchase Common Stock	3,984,484	3,793,388
Options to Purchase Common Stock	1,886,247	1,328,621
Convertible Preferred Stock	1,391,045	1,363,636
Unvested Restricted Stock Units	584,309	258,885
Unvested Restricted Stock Awards	891	891
Total	7,846,976	6,745,421

Schedule of Basic and Diluted Net Loss Per Share

The following table presents the calculation of basic and diluted EPS:

	Years Ended December 31,
	2024		2023
Numerator:
Net Loss	$	(480)	$	(8,439)
Accretion of Series X Preferred Stock	(302)		(150)
Net Loss Attributable to Common Stockholders	$	(782)	$	(8,589)
Denominator
Weighted Average Number of Shares of Common Stock Outstanding - Basic and Diluted	31,058,539		23,322,915
Net Loss Per Share Attributable to Common Stockholders - Basic and Diluted	$	(0.03)	$	(0.37)